12/5
03:16 pm
prax
How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story [Yahoo! Finance]
12/5
02:47 pm
prax
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 [Seeking Alpha]
Low
Report
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 [Seeking Alpha]
12/5
01:27 pm
prax
Top Midday Gainers [Yahoo! Finance]
Low
Report
Top Midday Gainers [Yahoo! Finance]
12/5
12:13 pm
prax
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $304.00 price target on by analysts at Needham & Company LLC.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $304.00 price target on by analysts at Needham & Company LLC.
12/5
10:59 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/5
09:11 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
12/5
08:44 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
12/5
08:08 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "underperform" rating reaffirmed by analysts at Wedbush.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "underperform" rating reaffirmed by analysts at Wedbush.
12/5
07:21 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/4
04:10 pm
prax
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
High
Report
Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
12/4
04:01 pm
prax
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
High
Report
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
12/3
04:01 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
08:09 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $250.00 price target on the stock.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $250.00 price target on the stock.
11/28
12:43 pm
prax
Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 [Seeking Alpha]
Low
Report
Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 [Seeking Alpha]
11/26
04:02 pm
prax
Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET [Seeking Alpha]
Medium
Report
Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET [Seeking Alpha]
11/26
02:14 pm
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
08:07 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $258.00 price target on the stock.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $258.00 price target on the stock.
11/24
04:01 pm
prax
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
Medium
Report
Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
11/21
05:31 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/20
04:37 pm
prax
Praxis Precision Medicines to Participate in Upcoming Fireside Chat [Yahoo! Finance]
Low
Report
Praxis Precision Medicines to Participate in Upcoming Fireside Chat [Yahoo! Finance]
11/20
04:01 pm
prax
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Medium
Report
Praxis Precision Medicines to Participate in Upcoming Fireside Chat
11/20
06:02 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
11/19
07:00 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $424.00 price target on by analysts at BTIG Research.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $424.00 price target on by analysts at BTIG Research.
11/13
08:11 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at HC Wainwright from $232.00 to $258.00. They now have a "buy" rating on the stock.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at HC Wainwright from $232.00 to $258.00. They now have a "buy" rating on the stock.
11/6
06:05 pm
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.